依达拉奉注射液联合盐酸普拉克索治疗老年血管性帕金森综合征的疗效及对氧化应激的影响
|
摘要
目的探讨依达拉奉注射液联合盐酸普拉克索治疗老年血管性帕金森综合征(VPS)临床疗效及对病人氧化应激的影响。方法将112例符合纳入标准的老年VPS病人随机分为对照组56例和观察组56例。常规治疗基础上,对照组给予盐酸普拉克索治疗,观察组在对照组基础上联合依达拉奉注射液治疗。比较2组病人临床疗效、帕金森病综合评分量表(UPDRS)评分、血清氧化应激指标水平及不良反应发生情况。结果经过治疗,观察组病人治疗总有效率高于对照组(87. 5%比71. 4%,P<0. 05)。治疗后,观察组病人UPDRS评分中的精神行为心境、日常生活活动、运动功能评分与对照组相比,均显著降低(P均<0. 05)。观察组病人血清丙二醛(MDA)水平低于对照组,超氧化物歧化酶(SOD)水平高于对照组(P均<0. 05)。结论依达拉奉注射液联合盐酸普拉克索在老年VPS中应用效果良好,能够有效改善病人临床症状,减轻氧化应激,且不良反应轻微。
Objective To investigate the curative efficacy of edaravone injection in combination with pramipexole dihydrochloride in the elderly patients with vascular Parkinson's syndrome( VPS) and its effects on oxidative stress. Methods A total of 112 elderly patients with VPS were randomly divided into control group( n = 56) and observation group( n = 56). Based on conventional treatments,the control group was treated with pramipexole dihydrochloride,and the observation group was treated with edaravone injection in combination with pramipexole dihydrochloride. The curative efficacy, scores of unified Parkinson's disease rating scale( UPDRS),levels of serum markers reflecting oxidative stress and adverse reactions were compared between the two groups. Results After treatment,the total therapeutic efficacy ratio in the observation group was statistically higher than that in the control group( 87. 5% vs 71. 4%,P<0. 05). In comparison with the control group after treatment,scores of mental,emotional and behavioral,activities of daily living and motor function in UPDRS were statistically lower in the observation group( all P<0. 05). In comparison with the control group after treatment,the observation group had lower level of malonaldehyde( MDA) and higher level of superoxide dismutase( SOD)( both P< 0. 05). During the treatment,there were no severe adverse reactions accurring in the two groups. And the incidence rate of adverse reactions in the control group and the observation group was 16. 1% and 21. 4% respectively with no statistical difference( P> 0. 05). Conclusions Edaravone injection in combination with pramipexole dihydrochloride has well application effect in the elderly patients with VPS,which can significantly improve clinical symptoms and alleviate oxidative stress with minor adverse reactions.
Objective To investigate the curative efficacy of edaravone injection in combination with pramipexole dihydrochloride in the elderly patients with vascular Parkinson's syndrome( VPS) and its effects on oxidative stress. Methods A total of 112 elderly patients with VPS were randomly divided into control group( n = 56) and observation group( n = 56). Based on conventional treatments,the control group was treated with pramipexole dihydrochloride,and the observation group was treated with edaravone injection in combination with pramipexole dihydrochloride. The curative efficacy, scores of unified Parkinson's disease rating scale( UPDRS),levels of serum markers reflecting oxidative stress and adverse reactions were compared between the two groups. Results After treatment,the total therapeutic efficacy ratio in the observation group was statistically higher than that in the control group( 87. 5% vs 71. 4%,P<0. 05). In comparison with the control group after treatment,scores of mental,emotional and behavioral,activities of daily living and motor function in UPDRS were statistically lower in the observation group( all P<0. 05). In comparison with the control group after treatment,the observation group had lower level of malonaldehyde( MDA) and higher level of superoxide dismutase( SOD)( both P< 0. 05). During the treatment,there were no severe adverse reactions accurring in the two groups. And the incidence rate of adverse reactions in the control group and the observation group was 16. 1% and 21. 4% respectively with no statistical difference( P> 0. 05). Conclusions Edaravone injection in combination with pramipexole dihydrochloride has well application effect in the elderly patients with VPS,which can significantly improve clinical symptoms and alleviate oxidative stress with minor adverse reactions.
引文
[1]Vizcarra JA,Lang AE,Sethi KD,et al.Vascular Parkinsonism:deconstructing a syndrome[J].Mov Disord,2015,30(7):886-894.
[2]张国平,贺茂林,王莉莉,等.血管性帕金森综合征临床特点分析[J].中国全科医学,2012,15(24):2805-2806.
[3]王雅娟,张秀敏,周华,等.补气破瘀息风法联合多巴丝肼治疗血管性帕金森综合征疗效观察[J].现代中西医结合杂志,2016,25(21):2316-2318.
[4]罗丹峰,吕瑞妍,朱凤瑛,等.盐酸普拉克索联合美多巴治疗血管性帕金森病的疗效观察[J].中国实用医药,2009,4(34):24-25.
[5]李芝兰,范永红.依达拉奉治疗血管性帕金森综合征疗效观察[J].中国基层医药,2016,23(1):51-54.
[6]马利萍,孙建国,彭英,等.依达拉奉清除自由基机制及临床应用[J].中国临床药理学与治疗学,2011,16(3):341-348.
[7]陈生弟.中国帕金森病治疗指南(第二版)[J].中华神经科杂志,2009,42(5):352-355.
[8]董婷,杨文明,王晓旸,等.灯盏细辛对早期血管性帕金森综合征的作用探讨[J].广东医学,2013,34(11):1759-1762.
[9]张秀敏,王雅娟.温阳逐瘀针刺疗法联合美多巴治疗血管性帕金森综合征临床观察[J].中西医结合心脑血管病杂志,2015,13(12):1442-1443.
[10]胡月丹.美多巴联合盐酸普拉克索治疗老年帕金森病的疗效及对运动功能的影响[J].中国老年学杂志,2015,35(23):6798-6800.
[11]谢均,晏玉奎,汤海燕,等.盐酸普拉克索对脑卒中后帕金森病患者的临床疗效[J].中国生化药物杂志,2016,36(11):84-87.
[12]顾卫霞,庄志清,王谟兰,等.帕金森患者血清同型半胱氨酸代谢、氧化应激程度与周围神经损害的相关性[J].海南医学院学报,2016,22(21):2625-2628.
[13]Zheng C,Liu S,Geng P,et al.Efficacy of edaravone on coronary artery bypass patients with myocardial damage after ischemia and reperfusion:a meta analysis[J].Int J Clin Exp Med,2015,8(2):2205-2211.
[14]张海三,张红星,张姣媚,等.Graves病患者外周血淋巴细胞NF-κB p65活性与血清丙二醛水平升高[J].实用医学杂志,2015,31(12):1954-1957.
[15]赵国莉,吕肖峰,程千鹏,等.胰岛素泵治疗对初诊2型糖尿病患者血糖、血脂、氧化应激的影响及胰岛β细胞与超氧化物歧化酶的关系研究[J].中国全科医学,2012,15(25):2902-2904.
[16]周红,张克忠,袁永胜,等.震颤型与姿势步态异常型帕金森病患者血浆抗氧化酶水平变化及意义[J].山东医药,2015,55(10):21-23.
[2]张国平,贺茂林,王莉莉,等.血管性帕金森综合征临床特点分析[J].中国全科医学,2012,15(24):2805-2806.
[3]王雅娟,张秀敏,周华,等.补气破瘀息风法联合多巴丝肼治疗血管性帕金森综合征疗效观察[J].现代中西医结合杂志,2016,25(21):2316-2318.
[4]罗丹峰,吕瑞妍,朱凤瑛,等.盐酸普拉克索联合美多巴治疗血管性帕金森病的疗效观察[J].中国实用医药,2009,4(34):24-25.
[5]李芝兰,范永红.依达拉奉治疗血管性帕金森综合征疗效观察[J].中国基层医药,2016,23(1):51-54.
[6]马利萍,孙建国,彭英,等.依达拉奉清除自由基机制及临床应用[J].中国临床药理学与治疗学,2011,16(3):341-348.
[7]陈生弟.中国帕金森病治疗指南(第二版)[J].中华神经科杂志,2009,42(5):352-355.
[8]董婷,杨文明,王晓旸,等.灯盏细辛对早期血管性帕金森综合征的作用探讨[J].广东医学,2013,34(11):1759-1762.
[9]张秀敏,王雅娟.温阳逐瘀针刺疗法联合美多巴治疗血管性帕金森综合征临床观察[J].中西医结合心脑血管病杂志,2015,13(12):1442-1443.
[10]胡月丹.美多巴联合盐酸普拉克索治疗老年帕金森病的疗效及对运动功能的影响[J].中国老年学杂志,2015,35(23):6798-6800.
[11]谢均,晏玉奎,汤海燕,等.盐酸普拉克索对脑卒中后帕金森病患者的临床疗效[J].中国生化药物杂志,2016,36(11):84-87.
[12]顾卫霞,庄志清,王谟兰,等.帕金森患者血清同型半胱氨酸代谢、氧化应激程度与周围神经损害的相关性[J].海南医学院学报,2016,22(21):2625-2628.
[13]Zheng C,Liu S,Geng P,et al.Efficacy of edaravone on coronary artery bypass patients with myocardial damage after ischemia and reperfusion:a meta analysis[J].Int J Clin Exp Med,2015,8(2):2205-2211.
[14]张海三,张红星,张姣媚,等.Graves病患者外周血淋巴细胞NF-κB p65活性与血清丙二醛水平升高[J].实用医学杂志,2015,31(12):1954-1957.
[15]赵国莉,吕肖峰,程千鹏,等.胰岛素泵治疗对初诊2型糖尿病患者血糖、血脂、氧化应激的影响及胰岛β细胞与超氧化物歧化酶的关系研究[J].中国全科医学,2012,15(25):2902-2904.
[16]周红,张克忠,袁永胜,等.震颤型与姿势步态异常型帕金森病患者血浆抗氧化酶水平变化及意义[J].山东医药,2015,55(10):21-23.